Zobrazeno 1 - 10
of 130
pro vyhledávání: '"Daniel L. Flynn"'
Autor:
Yasmin Yu, Madhumita Bogdan, Muhammad Zaeem Noman, Santiago Parpal, Elisabetta Bartolini, Kris Van Moer, Simone Caroline Kleinendorst, Kristine Bilgrav Saether, Lionel Trésaugues, Camilla Silvander, Johan Lindström, Jodi Simeon, Mary Jane Timson, Hikmat Al‐Hashimi, Bryan D. Smith, Daniel L. Flynn, Andrey Alexeyenko, Jenny Viklund, Martin Andersson, Jessica Martinsson, Katja Pokrovskaja Tamm, Angelo De Milito, Bassam Janji
Publikováno v:
Molecular Oncology, Vol 18, Iss 8, Pp 1904-1922 (2024)
An immunosuppressive tumor microenvironment promotes tumor growth and is one of the main factors limiting the response to cancer immunotherapy. We have previously reported that inhibition of vacuolar protein sorting 34 (VPS34), a crucial lipid kinase
Externí odkaz:
https://doaj.org/article/9dddee620d924c2eb795ae4895e7f6b3
Autor:
Jorge Cortes, Moshe Talpaz, Hedy P. Smith, David S. Snyder, Jean Khoury, Kapil N. Bhalla, Javier Pinilla-Ibarz, Richard Larson, David Mitchell, Scott C. Wise, Thomas J. Rutkoski, Bryan D. Smith, Daniel L. Flynn, Hagop M. Kantarjian, Oliver Rosen, Richard A. Van Etten
Publikováno v:
Haematologica, Vol 102, Iss 3 (2017)
A vailable tyrosine kinase inhibitors for chronic myeloid leukemia bind in an adenosine 5′-triphosphate-binding pocket and are affected by evolving mutations that confer resistance. Rebastinib was identified as a switch control inhibitor of BCR-ABL
Externí odkaz:
https://doaj.org/article/1ddbfc9f06d74ca0ace93112fc0c45e7
Autor:
Wen-Bin Ou, Christopher Hubert, Jonathan A. Fletcher, Joseph M. Corson, Raphael Bueno, Daniel L. Flynn, David J. Sugarbaker
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 13, Iss 1, Pp 12-22 (2011)
The receptor tyrosine kinases (RTKs) epidermal growth factor receptor (EGFR) and MET are activated in subsets of mesothelioma, suggesting that these kinases might represent novel therapeutic targets in this notoriously chemotherapy-resistant cancer.
Externí odkaz:
https://doaj.org/article/772963689c0a444cb1d0c46664a15ad1
Autor:
John S. Condeelis, Daniel L. Flynn, Joan G. Jones, Michele De Palma, Lawrence Chun, Yarong Wang, Maja H. Oktay, David Entenberg, Xiaoming Chen, Gada Al-Ani, Wei-Ping Lu, Cynthia B. Leary, Michael D. Kaufman, Molly M. Hood, Scott C. Wise, Ece Kadioglu, Bryan D. Smith, Jeanine Pignatelli, George S. Karagiannis, Allison S. Harney
Supplementary Material and Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c83205cee26a7b12a2993be79368f6da
https://doi.org/10.1158/1535-7163.22507510
https://doi.org/10.1158/1535-7163.22507510
Autor:
David S. Hong, Ramon V. Tiu, Michael S. Gordon, Ilaria Conti, Karim A. Benhadji, Sheng-Bin Peng, James R. Henry, Michael D. Kaufman, Daniel L. Flynn, KrisAnne Crowe, Andrew E. Schade, Danni Yu, Melinda D. Willard, Amanda Sykes, Ling Gao, Wei Zhang, Michael J. Millward, Jordi Rodon Ahnert, Geoffrey I. Shapiro, Keith T. Flaherty, Antoine Hollebecque, Ryan J. Sullivan
Supplementary Figure S2 shows two cases of patients treated at the RP2D. IHC at Clarient for p-ERK, p27 and Ki-67 were assessed for PD effect using monoclonal rabbit phospho-p44/42 MAPK (ERK1/2), 20G11 Clone; monoclonal mouse anti-Ki67, MIB-1 clone;
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4bffa344fba1fa66a45a3628b0bc99d4
https://doi.org/10.1158/1535-7163.22521469
https://doi.org/10.1158/1535-7163.22521469
Autor:
Daniel L. Flynn, Michael Clare, Lance J. Stewart, Lawrence Chun, Karen M. Yates, Subha Vogeti, Lakshminarayana Vogeti, Hanumaiah Telikepalli, Thiwanka Samarakoon, Thomas J. Rutkoski, William C. Patt, Tristan W. Patt, Wei-Ping Lu, Molly M. Hood, Carol L. Ensinger, Timothy M. Caldwell, R. John Booth, Yu Mi Ahn, Scott C. Wise, Benjamin A. Turner, Cynthia B. Leary, Michael D. Kaufman, Bryan D. Smith
Altiratinib (DCC-2701) was designed based on the rationale of engineering a single therapeutic agent able to address multiple hallmarks of cancer (1). Specifically, altiratinib inhibits not only mechanisms of tumor initiation and progression, but als
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4a49f1af80ca00d7cc02eb5848964921
https://doi.org/10.1158/1535-7163.c.6536815.v1
https://doi.org/10.1158/1535-7163.c.6536815.v1
Autor:
John S. Condeelis, Daniel L. Flynn, Joan G. Jones, Michele De Palma, Lawrence Chun, Yarong Wang, Maja H. Oktay, David Entenberg, Xiaoming Chen, Gada Al-Ani, Wei-Ping Lu, Cynthia B. Leary, Michael D. Kaufman, Molly M. Hood, Scott C. Wise, Ece Kadioglu, Bryan D. Smith, Jeanine Pignatelli, George S. Karagiannis, Allison S. Harney
Tumor-infiltrating myeloid cells promote tumor progression by mediating angiogenesis, tumor cell intravasation, and metastasis, which can offset the effects of chemotherapy, radiation, and antiangiogenic therapy. Here, we show that the kinase switch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::64e3696c40dea9ae99fa975de5b76e00
https://doi.org/10.1158/1535-7163.c.6538714.v1
https://doi.org/10.1158/1535-7163.c.6538714.v1
Autor:
Daniel L. Flynn, Michael Clare, Lance J. Stewart, Lawrence Chun, Karen M. Yates, Subha Vogeti, Lakshminarayana Vogeti, Hanumaiah Telikepalli, Thiwanka Samarakoon, Thomas J. Rutkoski, William C. Patt, Tristan W. Patt, Wei-Ping Lu, Molly M. Hood, Carol L. Ensinger, Timothy M. Caldwell, R. John Booth, Yu Mi Ahn, Scott C. Wise, Benjamin A. Turner, Cynthia B. Leary, Michael D. Kaufman, Bryan D. Smith
Supplementary Materials and Methods. Supplementary table 1: XRay crystallography parameters for DP-4157/MET complex. Supplementary table 2: Source and description of kinases. Supplementary table 3: Selectivity of profile of altiratinib inhibition fro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b914b7bf5b2f07136ac99e3d894850d
https://doi.org/10.1158/1535-7163.22501534
https://doi.org/10.1158/1535-7163.22501534
Autor:
Brian J. Druker, Thomas O'Hare, Michael W.N. Deininger, Daniel L. Flynn, Peter A. Petillo, Bryan D. Smith, Scott C. Wise, David J. Anderson, Mary Mac Partlin, Jeffrey W. Tyner, Lauren T. Adrian, Christopher A. Eide
Supplementary Tables 1-4, Figure 1 from The ABL Switch Control Inhibitor DCC-2036 Is Active against the Chronic Myeloid Leukemia Mutant BCR-ABLT315I and Exhibits a Narrow Resistance Profile
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a2432ac3c84471ba506f96d9dd9a62f
https://doi.org/10.1158/0008-5472.22392068
https://doi.org/10.1158/0008-5472.22392068
Autor:
Phaedra C. Ghazi, Conan Kinsey, Madhumita Bogdan, Bryan D. Smith, Daniel L. Flynn, Martin McMahon
Publikováno v:
Molecular Cancer Research. 21:PR03-PR03
Approximately 25% of lung cancers are driven by mutationally-activated KRAS. A major obstacle in treating lung cancer is resistance to current therapeutic treatments. The recent FDA approval of sotorasib, a direct pharmacological inhibitor of KRASG12